

Michael J Schell

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10671081/publications.pdf>

Version: 2024-02-01

56
papers

5,059
citations

109321

35
h-index

155660

55
g-index

56
all docs

56
docs citations

56
times ranked

7191
citing authors

#	ARTICLE	IF	CITATIONS
1	Testosterone and Dihydrotestosterone Tissue Levels in Recurrent Prostate Cancer. <i>Clinical Cancer Research</i> , 2005, 11, 4653-4657.	7.0	457
2	A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study. <i>Lancet Oncology</i> , The, 2017, 18, 202-211.	10.7	377
3	12-Chemokine Gene Signature Identifies Lymph Node-like Structures in Melanoma: Potential for Patient Selection for Immunotherapy?. <i>Scientific Reports</i> , 2012, 2, 765.	3.3	307
4	Phase III Trial Comparing a Defined Duration of Therapy Versus Continuous Therapy Followed by Second-Line Therapy in Advanced-Stage IIIB/IV Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2002, 20, 1335-1343.	1.6	297
5	A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer. <i>JAMA Oncology</i> , 2020, 6, 888.	7.1	293
6	Hormone-related Factors and Risk of Breast Cancer in Relation to Estrogen Receptor and Progesterone Receptor Status. <i>American Journal of Epidemiology</i> , 2000, 151, 703-714.	3.4	232
7	Safety, Correlative Markers, and Clinical Results of Adjuvant Nivolumab in Combination with Vaccine in Resected High-Risk Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2015, 21, 712-720.	7.0	225
8	Phase I/II Study of the Src Inhibitor Dasatinib in Combination With Erlotinib in Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 1387-1394.	1.6	184
9	A multigene mutation classification of 468 colorectal cancers reveals a prognostic role for APC. <i>Nature Communications</i> , 2016, 7, 11743.	12.8	170
10	Steroid 5 α -Reductase Isozymes I and II in Recurrent Prostate Cancer. <i>Clinical Cancer Research</i> , 2005, 11, 4365-4371.	7.0	166
11	Randomized Phase III Trial of Gemcitabine-Based Chemotherapy With In Situ RRM1 and ERCC1 Protein Levels for Response Prediction in Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 5808-5815.	1.6	164
12	Dose-escalating conformal thoracic radiation therapy with induction and concurrent carboplatin/paclitaxel in unresectable stage IIIA/B nonsmall cell lung carcinoma. <i>Cancer</i> , 2001, 92, 1213-1223.	4.1	160
13	Randomized International Phase III Trial of ERCC1 and RRM1 Expression-Based Chemotherapy Versus Gemcitabine/Carboplatin in Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 2404-2412.	1.6	143
14	The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, Stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel. <i>Cancer</i> , 2003, 98, 779-788.	4.1	130
15	Association of Recall Rates with Sensitivity and Positive Predictive Values of Screening Mammography. <i>American Journal of Roentgenology</i> , 2001, 177, 543-549.	2.2	125
16	Thoracotomy for pulmonary metastatic osteosarcoma. An analysis of prognostic indicators of survival. <i>Cancer</i> , 1987, 59, 374-379.	4.1	114
17	Lower prevalence of the debrisoquin oxidative poor metabolizer phenotype in American black versus white subjects. <i>Clinical Pharmacology and Therapeutics</i> , 1991, 50, 308-313.	4.7	105
18	Randomized, Placebo-Controlled Trial of Green Tea Catechins for Prostate Cancer Prevention. <i>Cancer Prevention Research</i> , 2015, 8, 879-887.	1.5	102

#	ARTICLE	IF	CITATIONS
19	Phase II study of sunitinib malate, a multitargeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on three prevalent histologies: Leiomyosarcoma, liposarcoma and malignant fibrous histiocytoma. <i>International Journal of Cancer</i> , 2011, 129, 1963-1969.	5.1	100
20	Evidence-based Target Recall Rates for Screening Mammography¹. <i>Radiology</i> , 2007, 243, 681-689.	7.3	87
21	Long-term follow-up of parental adjustment following a child's death at home or hospital. <i>Cancer</i> , 1989, 63, 988-994.	4.1	70
22	The Influence of a Low-Fat Diet on Incidence and Severity of Migraine Headaches. <i>Journal of Women's Health and Gender-Based Medicine</i> , 1999, 8, 623-630.	1.5	70
23	Small cell lung cancer in women: risk associated with smoking, prior respiratory disease, and occupation. <i>Lung Cancer</i> , 2000, 28, 1-10.	2.0	66
24	Immunohistochemical expression of neuron-specific enolase and leu 7 in Ewing's sarcoma of bone. <i>Cancer</i> , 1989, 64, 1266-1273.	4.1	64
25	Continuous Toxicity Monitoring in Phase II Trials in Oncology. <i>Biometrics</i> , 2005, 61, 540-545.	1.4	62
26	Factors associated with the likelihood of receiving second line therapy for advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2005, 47, 253-259.	2.0	60
27	ERCC1 and RRM1 in the International Adjuvant Lung Trial by Automated Quantitative in Situ Analysis. <i>American Journal of Pathology</i> , 2011, 178, 69-78.	3.8	59
28	ID1 Facilitates the Growth and Metastasis of Non-Small Cell Lung Cancer in Response to Nicotinic Acetylcholine Receptor and Epidermal Growth Factor Receptor Signaling. <i>Molecular and Cellular Biology</i> , 2011, 31, 3052-3067.	2.3	58
29	Second-line, low-dose, weekly paclitaxel in patients with stage IIIB/IV nonsmall cell lung carcinoma who fail first-line chemotherapy with carboplatin plus paclitaxel. <i>Cancer</i> , 2002, 95, 1265-1273.	4.1	55
30	The Reduced Monotonic Regression Method. <i>Journal of the American Statistical Association</i> , 1997, 92, 128-135.	3.1	52
31	Vertebral compression fracture as a presenting feature of acute lymphoblastic leukemia in children. <i>Cancer</i> , 1988, 61, 589-592.	4.1	47
32	In Vivo Percutaneous Absorption of Boric Acid, Borax, and Disodium Octaborate Tetrahydrate in Humans Compared to in Vitro Absorption in Human Skin from Infinite and Finite Doses. <i>Toxicological Sciences</i> , 1998, 45, 42-51.	3.1	46
33	Optimism bias leads to inconclusive resultsâ€”an empirical study. <i>Journal of Clinical Epidemiology</i> , 2011, 64, 583-593.	5.0	45
34	Preliminary indication of survival benefit from <i>ERCC1</i> and <i>RRM1</i>â€”tailored chemotherapy in patients with advanced nonsmall cell lung cancer: Evidence from an individual patient analysis. <i>Cancer</i> , 2012, 118, 2525-2531.	4.1	45
35	Randomized, placebo-controlled trial evaluating the safety of one-year administration of green tea catechins. <i>Oncotarget</i> , 2016, 7, 70794-70802.	1.8	41
36	Co-Evolution of Somatic Variation in Primary and Metastatic Colorectal Cancer May Expand Biopsy Indications in the Molecular Era. <i>PLoS ONE</i> , 2015, 10, e0126670.	2.5	36

#	ARTICLE	IF	CITATIONS
37	Factors Predicting Successful Needle-Localized Breast Biopsy. <i>Academic Radiology</i> , 2003, 10, 601-606.	2.5	32
38	Decision-Making When Data and Inferences Are Not Conclusive: Risk-Benefit and Acceptable Regret Approach. <i>Seminars in Hematology</i> , 2008, 45, 150-159.	3.4	26
39	Phase 2 trial of docetaxel and gefitinib in the first-line treatment of patients with advanced nonsmall-cell lung cancer (NSCLC) who are 70 years of age or older. <i>Cancer</i> , 2008, 112, 2021-2029.	4.1	25
40	Improved survival modeling in cancer research using a reduced piecewise exponential approach. <i>Statistics in Medicine</i> , 2014, 33, 59-73.	1.6	24
41	Adverse prognostic features in 251 children treated for acute myeloid leukemia. <i>Medical and Pediatric Oncology</i> , 1993, 21, 1-7.	1.0	19
42	Phase 1 trial of dasatinib combined with afatinib for epidermal growth factor receptor- (EGFR-) mutated lung cancer with acquired tyrosine kinase inhibitor (TKI) resistance. <i>British Journal of Cancer</i> , 2019, 120, 791-796.	6.4	16
43	Second-Line Gemcitabine in Refractory Stage IV Non-Small-Cell Lung Cancer: A Phase II Trial. <i>Clinical Lung Cancer</i> , 2000, 2, 133-138.	2.6	15
44	Carboplatin-based chemotherapy in patients with advanced non-small cell lung cancer and a poor performance status. <i>Lung Cancer</i> , 2006, 51, 237-243.	2.0	15
45	Repurposing EGFR Inhibitor Utility in Colorectal Cancer in Mutant <i>APC</i> and <i>TP53</i> Subpopulations. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 1141-1152.	2.5	15
46	In vivo percutaneous absorption of boron as boric acid, borax, and disodium octaborate tetrahydrate in humans. <i>Biological Trace Element Research</i> , 1998, 66, 101-109.	3.5	12
47	Green tea extract for prevention of prostate cancer progression in patients on active surveillance. <i>Oncotarget</i> , 2018, 9, 37798-37806.	1.8	9
48	Comparing Two Exponential Distributions Using the Exact Likelihood Ratio Test. <i>Statistics in Biopharmaceutical Research</i> , 2012, 4, 348-356.	0.8	8
49	Long-term supplementation of decaffeinated green tea extract does not modify body weight or abdominal obesity in a randomized trial of men at high risk for prostate cancer. <i>Oncotarget</i> , 2017, 8, 99093-99103.	1.8	8
50	Testing Violations of the Exponential Assumption in Cancer Clinical Trials with Survival Endpoints. <i>Biometrics</i> , 2017, 73, 687-695.	1.4	6
51	In vitro percutaneous absorption of boron as boric acid, borax, and disodium octaborate tetrahydrate in human skin. <i>Biological Trace Element Research</i> , 1998, 66, 111-120.	3.5	5
52	Coordinated Pembrolizumab and High Dose IL-2 (5-in-a-Row Schedule) for Therapy of Metastatic Clear Cell Renal Cancer. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 252-259.	1.9	4
53	Recall and detection rates in screening mammography. <i>Cancer</i> , 2004, 101, 2710-2711.	4.1	3
54	Modeling precision genomic-based radiation dose response in rectal cancer. <i>Future Oncology</i> , 2020, 16, 2411-2420.	2.4	2

#	ARTICLE	IF	CITATIONS
55	Circulating Immunosuppressive Regulatory T Cells Predict Risk of Incident Cutaneous Squamous Cell Carcinoma. <i>Frontiers in Medicine</i> , 2021, 8, 735585.	2.6	1
56	Need for More Comprehensive Evaluation of Immune-Related Adverse Events in Immunotherapy for Biliary Tract Cancer—Reply. <i>JAMA Oncology</i> , 2020, 6, 1981.	7.1	0